Skip to main content
To the Editor: Dr. Smith asks an important question, namely if “d-cycloserine augmentation of virtual reality exposure therapy appeared to be associated with worse outcomes for the subset of patients experiencing little response or worsening of subjective distress during the treatment.” The figure and analysis to which Dr. Smith refers are implied from a mixed-effect model that included all participants (N=156). Different outcomes were discovered based on different measures in this study. The most robust beneficial effects of d-cycloserine were seen in the more objective measures of psychophysiological startle and salivary cortisol, consistent with the animal literature on the facilitation of extinction by d-cycloserine. Less consistent were the posttraumatic stress disorder (PTSD) clinical measures that were all based on patient self-report. Even though the Clinician Administered PTSD Scale is a clinical interview, it is based on patient self-report of PTSD symptoms. Even more subjective is the Subjective Units of Distress Scale, which the analysis of emotional learning within and between sessions (to which Dr. Smith refers) is based. Using raw change in Clinician Administered PTSD Scale scores as an indicator of treatment response, we identified two participants in the d-cycloserine condition who had worse symptoms at posttreatment relative to pretreatment. This was less than the six participants in the alprazolam condition and eight in the placebo condition who had worse symptoms at posttreatment relative to pretreatment. The two participants in the d-cycloserine condition with negative scores did not demonstrate negative emotional learning. The graphs in the figure correspond to model-implied trajectories, suggesting that it is theoretically possible that a participant with sufficient negative emotional learning could have poorer outcomes with d-cycloserine relative to a lack of d-cycloserine. This phenomena, however, was not observed in our current sample. Furthermore, the graphs we presented correspond to response in the d-cycloserine condition relative to change in the placebo or alprazolam conditions. That is, these graphs suggest that the negative outcomes obtained are relative to other conditions as opposed to overall functioning. Dr. Smith then suggests “adding the d-cycloserine or a similar agent after the first couple of sessions and only for that subset of patients that have already started to experience a positive response to the treatment.” We think this is a very interesting and important idea, and it is similar to what has been attempted in several recent trials of d-cycloserine combined with exposure therapy (13). Most of these have found benefit only for those patients who demonstrated emotional learning within that session, as was found in our study administering d-cycloserine 30 minutes prior to exposure therapy. We absolutely agree with Dr. Smith’s suggestions to determine who is most likely to respond well to exposure therapy and to exposure therapy combined with cognitive enhancers. In this study, those patients who displayed larger startle responses prior to treatment and had lower salivary cortisol in response to the virtual scenes embedded with acoustic startle probes fared better when the virtual reality exposure therapy was combined with d-cycloserine compared with alprazolam or placebo.

References

1.
Smits JA, Rosenfield D, Otto MW, Powers MB, Hofmann SG, Telch MJ, Pollack MH, Tart CD: d-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 2013; 73:1054–1058
2.
Tart CD, Handelsman PR, Deboer LB, Rosenfield D, Pollack MH, Hofmann SG, Powers MB, Otto MW, Smits JA: Augmentation of exposure therapy with post-session administration of d-cycloserine. J Psychiatr Res 2013; 47:168–174
3.
Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR: A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63:544–549

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1223 - 1224
PubMed: 25756637

History

Accepted: August 2014
Published online: 1 November 2014
Published in print: November 01, 2014

Authors

Details

Barbara Olasov Rothbaum, Ph.D., A.B.P.P.
From the Trauma and Anxiety Recovery Program, Emory University School of Medicine, Atlanta; the University of Vermont, Burlington, Vt.; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.
Matthew Price, Ph.D.
From the Trauma and Anxiety Recovery Program, Emory University School of Medicine, Atlanta; the University of Vermont, Burlington, Vt.; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.
Kerry Ressler, M.D., Ph.D.
From the Trauma and Anxiety Recovery Program, Emory University School of Medicine, Atlanta; the University of Vermont, Burlington, Vt.; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.

Funding Information

The authors’ disclosures accompany the original article.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share